Ikena Oncology Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

IMA$3.81-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Collaboration revenue	$—	$2,004	$—	$7,316
Operating expenses:
Research and development	9,832	15,172	19,477	30,723
General and administrative	5,308	5,322	11,307	10,598
Restructuring and other charges	683	—	3,265	—
Total operating expenses	15,823	20,494	34,049	41,321
Loss from operations	(15,823)	(18,490)	(34,049)	(34,005)
Other income (expense):
Investment income	1,920	1,381	4,034	2,677
Other income (expense)	235	(6)	228	(6)
Total other income, net	2,155	1,375	4,262	2,671
Loss before income taxes	(13,668)	(17,115)	(29,787)	(31,334)
Income tax expense	(62)	—	(89)	—
Net loss	$(13,730)	$(17,115)	$(29,876)	$(31,334)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(37)	35	(302)	307
Total comprehensive loss	$(13,767)	$(17,080)	$(30,178)	$(31,027)
Net loss per share:
Net loss per share, basic and diluted	$(0.28)	$(0.44)	$(0.62)	$(0.83)
Weighted-average common shares outstanding, basic and diluted	48,258,111	39,292,710	48,258,111	37,783,486

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.